{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:55:36Z","timestamp":1793141736424,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T00:00:00Z","timestamp":1424390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Selisistat (<jats:styled-content style=\"fixed-case\">SEN0014196<\/jats:styled-content>), a first\u2010in\u2010class <jats:styled-content style=\"fixed-case\">SirT1<\/jats:styled-content> inhibitor, is being developed as a disease\u2010modifying therapy for <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>untington's disease. This first\u2010in\u2010human study investigated the safety, pharmacokinetics and pharmacogenomics of single and multiple doses of selisistat in healthy male and female subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In this double\u2010blind, randomized, placebo\u2010controlled study, seven cohorts of eight subjects received a single dose of selisistat at dose levels of 5, 25, 75, 150, 300 and 600\u2009mg and four cohorts of eight subjects were administered 100, 200 and 300\u2009mg once daily for 7 days. Blood sampling and safety assessments were conducted throughout the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Selisistat was rapidly absorbed and systemic exposure increased in proportion to dose in the 5\u2013300\u2009mg range. Steady\u2010state plasma concentrations were achieved within 4 days of repeated dosing. The incidence of drug related adverse events showed no correlation with dose level or number of doses received and was comparable with the placebo group. No serious adverse events were reported and no subjects were withdrawn due to adverse events. There were no trends in clinical laboratory parameters or vital signs. No trends in heart rate or <jats:styled-content style=\"fixed-case\">ECG<\/jats:styled-content> parameters, including the <jats:styled-content style=\"fixed-case\">QT<jats:sub>c<\/jats:sub><\/jats:styled-content> interval and <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010wave morphology, were observed. There were no findings in physical or neurological examinations or postural control. Transcriptional alteration was observed in peripheral blood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Selisistat was safe and well tolerated by healthy male and female subjects after single doses up to 600\u2009mg and multiple doses up to 300\u2009mg\u2009day<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12513","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T04:48:07Z","timestamp":1410842887000},"page":"477-491","source":"Crossref","is-referenced-by-count":60,"title":["Safety, pharmacokinetics, pharmacogenomics and <scp>QT<\/scp> concentration\u2212effect modelling of the <scp>SirT1<\/scp> inhibitor selisistat in healthy volunteers"],"prefix":"10.1111","volume":"79","author":[{"given":"Goran","family":"Westerberg","sequence":"first","affiliation":[{"name":"Siena Biotech SpA  35, Strada del Petriccio e Belriguardo 53100 Siena Italy"},{"name":"La Crocina Pharmaceutical Consultants D.I.  Podere La Crocina 53020 San Giovanni d'Asso Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Chiesa","sequence":"additional","affiliation":[{"name":"Covance Clinical Research Ltd  Springfield House Leeds LS2\u20099LH West Yorkshire United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus A.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Siena Biotech SpA  35, Strada del Petriccio e Belriguardo 53100 Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Diamanti","sequence":"additional","affiliation":[{"name":"Siena Biotech SpA  35, Strada del Petriccio e Belriguardo 53100 Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Magnoni","sequence":"additional","affiliation":[{"name":"Siena Biotech SpA  35, Strada del Petriccio e Belriguardo 53100 Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pollio","sequence":"additional","affiliation":[{"name":"Siena Biotech SpA  35, Strada del Petriccio e Belriguardo 53100 Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje","family":"Darpo","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Division of Cardiovascular Medicine Karolinska Institute Danderyd's Hospital  Stockholm Sweden"},{"name":"iCardiac Technologies, Inc.  150 Allens Creek Road Rochester NY 14618 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijian","family":"Zhou","sequence":"additional","affiliation":[{"name":"iCardiac Technologies, Inc.  150 Allens Creek Road Rochester NY 14618 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"e_1_2_9_4_1","first-page":"251","volume-title":"Huntington's Disease","author":"Gutekunst C","year":"2002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200403000-00001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5334.1990"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.03.018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn273"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720506778249407"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(02)00709-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1989"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920107783018417"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050522v"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu010"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JHD-120042","article-title":"Reference genes selection for transcriptional profiling in blood of HD patients and R6\/2 mice","volume":"2","author":"Diamanti D","year":"2013","journal-title":"J Huntingtons Dis"},{"key":"e_1_2_9_16_1","first-page":"401","article-title":"Improving the precision of QT measurements","volume":"18","author":"Darpo B","year":"2011","journal-title":"Cardiol J"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gng015"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-28"},{"key":"e_1_2_9_19_1","unstructured":"Siena Biotech SpA. Data on file."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12068"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009341184"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12128"},{"key":"e_1_2_9_23_1","unstructured":"ICH harmonized tripartite guideline E14. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs.2005. Available athttp:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf(last accessed September 2014)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12513","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T22:04:02Z","timestamp":1694469842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,20]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bcp.12513"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12513","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,20]]}}}